Blichert-Toft M, Brincker H, Andersen J A, Andersen K W, Axelsson C K, Mouridsen H T, Dombernowsky P, Overgaard M, Gadeberg C, Knudsen G
Surgical Department of Odense, Odense University Hospital.
Acta Oncol. 1988;27(6A):671-7. doi: 10.3109/02841868809091767.
The present study comprises 847 women operated upon for invasive breast carcinoma at 19 surgical departments and enrolled in protocol DBCG-82TM from January 1983 to November 1987. Among them 662 (78%) were allocated for breast-preserving therapy or mastectomy by randomization, while 185 patients (22%) did not accept randomization. Within the randomized group 6% could not be entered into adjuvant protocols, i.e. subsequent programmes of postoperative therapy and follow-up. This left 619 evaluable patients. In the non-randomized series 26% did not fulfil the demands for entrance into the adjuvant protocols, leaving 136 evaluable patients, 60 of whom had chosen a breast-preserving operation and 76 mastectomy. In the randomized series the patients in the two treatment arms were comparable in age, menopausal status, site of tumour, pathoanatomical diameter of the tumour, number of removed axillary lymph nodes, number of metastatic axillary lymph nodes, and distribution on adjuvant regimens. Ninety per cent of the patients in the randomized group accepted the method offered, whereas 10% declined and wanted the alternate form of operation. The median follow-up period was approximately 1.75 years. The cumulative recurrence rate in the randomized group was 13% and in the non-randomized group 7%. These results are preliminary. Life-table analyses have not so far demonstrated differences in recurrence-free survival either in the randomized or the non-randomized series.
本研究纳入了1983年1月至1987年11月期间在19个外科科室接受浸润性乳腺癌手术且参与DBCG - 82TM方案的847名女性。其中662名(78%)通过随机分组接受保乳治疗或乳房切除术,而185名患者(22%)未接受随机分组。在随机分组的患者中,6%无法进入辅助治疗方案,即后续的术后治疗和随访计划。这样就剩下619名可评估患者。在非随机分组的系列中,26%不符合进入辅助治疗方案的要求,剩下136名可评估患者,其中60名选择了保乳手术,76名选择了乳房切除术。在随机分组系列中,两个治疗组的患者在年龄、绝经状态、肿瘤部位、肿瘤的病理解剖直径、切除腋窝淋巴结的数量、腋窝转移淋巴结的数量以及辅助治疗方案的分布方面具有可比性。随机分组组中90%的患者接受了提供的治疗方法,而10%的患者拒绝并希望采用另一种手术方式。中位随访期约为1.75年。随机分组组的累积复发率为13%,非随机分组组为7%。这些结果是初步的。到目前为止,生存分析尚未显示随机分组系列或非随机分组系列在无复发生存方面存在差异。